Cantitate/Preț
Produs

Small Molecules in Oncology: Recent Results in Cancer Research, cartea 184

Editat de Uwe M. Martens
en Limba Engleză Paperback – 4 mai 2012
Extensive research into the molecular mechanisms of cancer disease has heralded a new age of targeted therapy. In malignant cells, key proteins that are crucial to tumor growth and survival are now being targeted directly with rationally designed inhibitors. Apart from monoclonal antibodies, small molecule therapeutics such as oncogenic protein kinase inhibitors are attracting a vast amount of investigational attention. This textbook, written by acknowledged experts, provides a broad overview of the small molecules currently used for the treatment of malignant diseases and discusses interesting novel compounds that are in the process of clinical development to combat cancer.
Citește tot Restrânge

Toate formatele și edițiile

Toate formatele și edițiile Preț Express
Paperback (3) 84137 lei  43-57 zile
  Springer International Publishing – 5 ian 2019 84137 lei  43-57 zile
  Springer Berlin, Heidelberg – 23 aug 2016 90643 lei  43-57 zile
  Springer Berlin, Heidelberg – 4 mai 2012 165456 lei  43-57 zile
Hardback (2) 73055 lei  43-57 zile
  Springer Berlin, Heidelberg – 12 mai 2014 73055 lei  43-57 zile
  Springer International Publishing – 13 aug 2018 84830 lei  43-57 zile

Din seria Recent Results in Cancer Research

Preț: 165456 lei

Preț vechi: 174164 lei
-5% Nou

Puncte Express: 2482

Preț estimativ în valută:
31668 32635$ 26736£

Carte tipărită la comandă

Livrare economică 03-17 martie

Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9783642261459
ISBN-10: 3642261450
Pagini: 256
Ilustrații: XVI, 238 p.
Dimensiuni: 155 x 235 x 13 mm
Greutate: 0.39 kg
Ediția:2010
Editura: Springer Berlin, Heidelberg
Colecția Springer
Seria Recent Results in Cancer Research

Locul publicării:Berlin, Heidelberg, Germany

Public țintă

Professional/practitioner

Cuprins

Protein kinase inhibitors.- Imatinib Mesylate.- Erlotinib.- Axitinib (AG-013736).- Lapatinib.- Sorafenib.- Sunitinib.- Dasatinib.- Nilotinib.- Bosutinib.- Epigenetic modifiers.- Decitabine.- 5-Azacytidine/Azacitidine.- Cell cycle inhibitors.- Bortezomib.- Temsirolimus.- Danusertib (formerly PHA-739358) – A Novel Combined Pan-Aurora Kinases and Third Generation Bcr-Abl Tyrosine Kinase Inhibitor.- BI_2536 - Targeting the Mitotic Kinase Polo-Like Kinase 1 (Plk1).- Other novel agents.- Imetelstat (GRN163L) - Telomerase-Based Cancer Therapy.- GDC-0449 - Targeting the Hedgehog Signaling Pathway.

Textul de pe ultima copertă

Extensive research into the molecular mechanisms of cancer disease has heralded a new age of targeted therapy. In malignant cells, key proteins that are crucial to tumor growth and survival are now being targeted directly with rationally designed inhibitors. Apart from monoclonal antibodies, small molecule therapeutics such as oncogenic protein kinase inhibitors are attracting a vast amount of investigational attention. This textbook, written by acknowledged experts, provides a broad overview of the small molecules currently used for the treatment of malignant diseases and discusses interesting novel compounds that are in the process of clinical development to combat cancer.

Caracteristici

Provides a broad overview of the small molecules currently used for the treatment of malignant diseases Discusses interesting novel compounds that are in the process of clinical development to combat cancer Written by acknowledged experts Includes supplementary material: sn.pub/extras

Notă biografică

Uwe Martens, Prof. Dr. med., is chair of the Cancer Center Heilbronn-Franken and head of the Department of Hematology and Oncology at the SLK Clinic Heilbronn, which is an academic teaching hospital of the University of Heidelberg. He graduated in Medicine from the University of Freiburg and continued his medical and scientific training at the Medical University Center in Freiburg and at the BC Cancer Research Center in Vancouver. His scientific focus is the development of personalized cancer therapy and immunotherapy. He is a co-founder of the MOLIT Institute for Personalized Medicine at the science and technology park in Heilbronn, which aims to rapidly translate precision medicine into standard care.

Recenzii

“The book is recommended for healthcare professionals, scientists, and students in medical and scientific fields. In 25 well-written chapters, experts in their fields of research describe in great detail 12 compounds currently in clinical use for the treatment of hematological malignancies, and 13 compounds applicable to specific mutation-containing malignancies or aimed at interfering with the microenvironment (such as angiogenesis). … This book provides important practical information on a wide variety of novel small molecule-based treatment approaches.” (George Somlo, Doody's Book Reviews, April, 2015)